By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc. (CNSP)

NASDAQ Currency in USD
$28.00
+$0.05
+0.17%
Last Update: 18 Jul 2026, 18:04
$12.41m
Market Cap
-0.94
P/E Ratio (TTM)
Forward Dividend Yield
$19.70-$33.70
52 Week Range

CNSP Stock Price Chart

Explore CNS Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze CNSP price movements and trends.

CNSP Company Profile

Discover essential business fundamentals and corporate details for CNS Pharmaceuticals, Inc. (CNSP) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Biotechnology

IPO Date

8 Nov 2019

Employees

4.00

CEO

Rami Levin

Description

CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.

CNSP Financial Timeline

Browse a chronological timeline of CNS Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 17 Aug 2026

EPS estimate is -$0.24.

Earnings released on 14 May 2026

EPS came in at -$7.30 falling short of the estimated -$5.37 by -35.94%.

Earnings released on 31 Mar 2026

EPS came in at -$5.09 matching the estimated -$5.09.

Earnings released on 14 Nov 2025

EPS came in at -$5.76 surpassing the estimated -$6.63 by +13.12%.

Earnings released on 14 Aug 2025

EPS came in at -$6.42 surpassing the estimated -$9.60 by +33.13%.

Stock split effective on 22 Jul 2025

Shares were split 1 : 12 , changing the number of shares outstanding and the price per share accordingly.

Stock split effective on 21 Feb 2025

Shares were split 1 : 50 , changing the number of shares outstanding and the price per share accordingly.

Earnings released on 14 Nov 2024

EPS came in at -$150.06 falling short of the estimated -$0.10 by -149.96k%.

Earnings released on 14 Aug 2024

EPS came in at -$4.03k falling short of the estimated -$3.59k by -12.50%.

Stock split effective on 5 Jun 2024

Shares were split 1 : 50 , changing the number of shares outstanding and the price per share accordingly.

Earnings released on 15 May 2024

EPS came in at -$12.30k .

Earnings released on 1 Apr 2024

EPS came in at -$28.51k surpassing the estimated -$57.00k by +49.98%, while revenue for the quarter reached $6.36k .

Earnings released on 14 Nov 2023

EPS came in at -$32.41k surpassing the estimated -$51.90k by +37.55%.

Earnings released on 14 Aug 2023

EPS came in at -$31.21k surpassing the estimated -$84.60k by +63.11%.

Earnings released on 15 May 2023

EPS came in at -$77.73k .

Earnings released on 31 Mar 2023

EPS came in at -$2.23 surpassing the estimated -$6.00k by +99.96%.

Stock split effective on 29 Nov 2022

Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.

Earnings released on 10 Nov 2022

EPS came in at -$8.10k falling short of the estimated -$2.40 by -337.57k%.

Earnings released on 12 Aug 2022

EPS came in at -$8.10k falling short of the estimated -$2.40 by -337.57k%.

Earnings released on 16 May 2022

EPS came in at -$6.30k falling short of the estimated -$2.40 by -262.53k%.

Earnings released on 3 Mar 2022

EPS came in at -$9.00k surpassing the estimated -$18.91k by +52.38%.

Earnings released on 12 Nov 2021

EPS came in at -$12.61k surpassing the estimated -$18.91k by +33.33%.

Earnings released on 13 Aug 2021

EPS came in at -$13.51k surpassing the estimated -$14.41k by +6.25%.

CNSP Stock Performance

Access detailed CNSP performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run